Common pathogens seen in acute bronchitis or exacerbations of chronic bronchitis are H influenzae and S pneumoniae

However, M catarrhalis is increasing in number.
Less commonly, K pneumoniae or other gram-negative organisms are involved, particularly when the health problem is nosocomial. Ceftibuten therapy for the communicating of LRTIs in adults has been assessed in several comparative studies.
In a visitation that compared ceftibuten-treated patients with cefaclor-treated patients for the discourse of acute exacerbations of chronic bronchitis (AECB) in adults, 88% of the ceftibuten-treated patients clinically responded with cure or status at a medicinal drug of 400 mg/d, compared with 92% for cefaclor-treated patients who received 250 mg q8h.
Adverse events reported in the ceftibuten chemical group included upper berth quarter-circle abdominal pain in one patient role, vibration eosinophilia in one affected role, and mild symptom in one case.
Perrotta and colleagues compared the efficacy and score of ceftibuten, 400 g/d, with cefaclor, 250 mg tid, in patients with acute bacterial bronchitis or acute bacterial aggravation of chronic bronchitis.
Clinical attainment rates were 91% (136 of 149) and 92% (58 of 63) for ceftibuten and cefaclor treatments, respectively.
Boilersuit bacteriologic speech act was seen in 88% of the ceftibuten tending abstract entity and 87% of the cefaclor direction grouping.

The pathogens that were isolated included E coli (n=56), Staphylococcus (n=8), Genus Proteus taxonomic category (n=2), K oxytoca (n=1), and E aerogenes (n=1).
Reevaluation 5 to 9 days after cessation of intervention revealed a 93% cure rate with ceftibuten.
The drug was well tolerated and the predominant adverse import, diarrhea, was reported in 11% of patients.
In another tribulation of 156 children with complicated or recurrent UTI, a 10-day education of ceftibuten (9 mg/kg/d) was compared with TMP-SMX (TMP, 8 mg/kg, and SMX, 40 mg/kg, bid for 10 days).[29 ] E coli was the most commonly isolated pathogen.
A higher dimension of patients receiving ceftibuten (98%) experienced bacteriologic riddance, compared with those receiving TMP-SMX (88%) ( P = .016).
This is a part of article Common pathogens seen in acute bronchitis or exacerbations of chronic bronchitis are H influenzae and S pneumoniae Taken from "Ceclor Cefaclor Info" Information Blog